For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
News Release
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring a…
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM) and…
Search Posts
Blog
Missing the economists in FTC’s latest PBM study
The Federal Trade Commission (FTC) released its not-so-objectively titled interim report on Pharmacy Benefit Managers (PBMs): Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug…
News Release
New FTC study on drug costs fails to conduct empirical analysis of market conditions
The Federal Trade Commission (FTC) release a new study today claiming Pharmacy Benefit Managers (PBMs) are responsible for higher drug costs. FTC Commissioner Melissa Holyoak…
Penn Live
Harrisburg is taking a wrong approach to drug pricing | PennLive letters
CEI’s Joel Zinberg was cited in a Penn Live article on Pharmacy Benefit Managers: Joel Zinberg from the Competitive Enterprise Institute (CEI) explains, “PBMs enhance…
Politico
Biden’s got a plan to protect science from Trump
CEI’s Joel Zinberg was cited in Politico on the obstacles Trump faces with the NIH: Trump should have no illusions about what he’s up against,…
Blog
New FDA lab tests rule could bankrupt small labs
Yesterday the Food and Drug Administration (FDA) announced that on May 6 it will promulgate a rule under its authority to regulate medical devices.
National Review
The Return of the Cadillac Tax?
Like the phoenix, a key piece of the Affordable Care Act has risen from the ashes, resurrected, believe it or not, by the Republican Study Committee…